• Skip to primary navigation
  • Skip to main content
  • Skip to footer

TVM Capital Life Science Venture Capital

Investing in Life Science Innovation

  • About Us
    • Partners
  • Team
  • Senior Advisors
  • Portfolio
  • Funding Request
  • News
  • Events
  • ESG Policy
  • Contact

Wilex

  • Home
  • About Us
  • Team
  • Senior Advisors
  • Portfolio
  • News
  • Events
  • ESG Policy
  • Contact

News · February 27, 2012

FDA approves protocol amendment needed to conduct the final analysis of the pivotal RENCAREX® Phase III trial

Munich, Germany, 27 February 2012. WILEX AG (ISIN DE0006614720 / WL6 / FSE) today announced that the US Food and Drug Administration (FDA) approved the protocol amendment for the pivotal Phase III …

News · June 17, 2011

WILEX reports on the Pre-BLA Meeting with the FDA and the next steps in the REDECTANE® approval process

Munich, 17 June 2011. WILEX AG (ISIN DE0006614720 / WL6 / Frankfurt Stock Exchange) today announced that the Pre-BLA Meeting with the American Food and Drug Administration planned for the second …

News · May 2, 2011

WILEX grants exclusive US commercialisation rights for RENCAREX® to Prometheus

Munich, Germany, 02 May, 2011. WILEX AG (ISIN DE0006614720, Frankfurt Stock Exchange) announced the granting of US commercialisation rights for RENCAREX® (Girentuximab) to Prometheus Laboratories Inc. …

News · April 14, 2011

WILEX veröffentlicht Finanzbericht für erstes Quartal 2011

• Finanzzahlen im Rahmen der Planung • Gesellschafterdarlehen erhalten • Zwischenanalyse zur Wirksamkeit für RENCAREX® gestartet • Akquisition der Heidelberg Pharma AG erfolgreich …

News · February 22, 2011

WILEX reports on the successful financial year 2010

• Strategic expansion of the value chain • Significant progress of all clinical projects • Financials in line with guidance Munich, Germany, 22 February 2011. WILEX AG (ISIN DE0006614720 / Frankfurt …

News · January 24, 2011

WILEX announces start of interim analysis for its Phase III ARISER registration trial with RENCAREX®

Munich, Germany, 24 January, 2011. WILEX AG (ISIN DE0006614720 / WL6 / Frankfurt Stock Exchange) today announced the achievement of a major clinical milestone. Over 340 recurrences have now been …

  • in

Copyright © 2023 · TVM Capital Life Science Venture Capital · ESG Disclosure · Privacy Policy · Contact